使用Box-Behnken设计,其表征和抗癌评估来制备重新使用的selecoxib载入的纳米结构脂质载体
Ashwini Bhavar1, Kaustubh Ajit Kolekar2, Tejashree Yadav1
1Department of Pharmaceutics, Tatyasaheb Kore College of Pharmacy, Warananagar, Tal: Panhala, Dist: Kolhapur, Maharashtra, 416 113, India.
Annales pharmaceutiques francaises
|March 28, 2025
概括
通过纳米结构脂质载体输送的重用赛莱科西布为肺癌提供了一种新的亲肠治疗方法. 这种方法提高了疗效,减少了副作用,改善了患者的治疗结果.
科学领域:
- 纳米技术在药物输送中的应用
- 制药科学 制药科学
- 在瘤学瘤学.
背景情况:
- 肺癌仍然是全球癌症相关死亡的主要原因.
- 重新利用现有药物,如赛莱科西布,为新型癌症疗法提供了一个有希望的途径.
- 塞莱科克西布的挑战包括溶解性差,生物可用性和潜在的副作用.
研究的目的:
- 开发载有赛莱可西布的纳米结构脂质载体 (NLCs),用于有效治疗亲肠肺癌.
- 为了克服传统赛莱科克西布管理的局限性.
- 为了提高治疗效果并最大限度地减少不良影响.
主要方法:
- 装有塞莱科克西布的NLCs是使用融乳化超声波技术制造的.
- 使用Box-Behnken设计进行了配方优化.
- 描述包括粒子大小,捕获效率,泽塔潜力,体外释放,细胞毒性和稳定性研究.
主要成果:
- 优化的NLC显示出高捕获效率 (91.69%) 和最佳颗粒大小 (132.1nm).
- 在48小时内观察到受控的药物释放和增强的体外细胞毒性 (1.5倍) 对A549肺癌细胞.
- 在12周内,NLCs表现出瘤向潜力和稳定性.
结论:
- 通过肠道给予塞莱科西布载荷的NLC是一种安全有效的肺癌治疗策略.
- 这种新的纳米载体系统改善了塞莱科克西布的治疗特性.
- 通过NLCs输送的重定位赛莱科克西布在肺癌治疗中呈现出一个有前途的新选择.
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...